CY1122551T1 - Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων - Google Patents
Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτωνInfo
- Publication number
- CY1122551T1 CY1122551T1 CY20191100155T CY191100155T CY1122551T1 CY 1122551 T1 CY1122551 T1 CY 1122551T1 CY 20191100155 T CY20191100155 T CY 20191100155T CY 191100155 T CY191100155 T CY 191100155T CY 1122551 T1 CY1122551 T1 CY 1122551T1
- Authority
- CY
- Cyprus
- Prior art keywords
- obese
- morbidly
- patient
- methods
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- YCGBUPXEBUFYFV-UHFFFAOYSA-N withaferin A Natural products CC(C1CC(=C(CO)C(=O)O1)C)C2CCC3C4CC5OC56C(O)C=CC(O)C6(C)C4CCC23C YCGBUPXEBUFYFV-UHFFFAOYSA-N 0.000 abstract 2
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 abstract 2
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000014101 glucose homeostasis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908998P | 2013-11-26 | 2013-11-26 | |
| PCT/US2014/067393 WO2015081093A1 (en) | 2013-11-26 | 2014-11-25 | Compounds for the treatment of obesity and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122551T1 true CY1122551T1 (el) | 2021-01-27 |
Family
ID=52134396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100155T CY1122551T1 (el) | 2013-11-26 | 2019-02-05 | Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160375039A1 (enExample) |
| EP (1) | EP3074033B1 (enExample) |
| JP (2) | JP6672157B2 (enExample) |
| AU (2) | AU2014354831B2 (enExample) |
| CA (1) | CA2931826C (enExample) |
| CY (1) | CY1122551T1 (enExample) |
| DK (1) | DK3074033T3 (enExample) |
| ES (1) | ES2709976T3 (enExample) |
| HR (1) | HRP20190219T1 (enExample) |
| HU (1) | HUE042196T2 (enExample) |
| LT (1) | LT3074033T (enExample) |
| PL (1) | PL3074033T3 (enExample) |
| PT (1) | PT3074033T (enExample) |
| RS (1) | RS58422B1 (enExample) |
| SI (1) | SI3074033T1 (enExample) |
| SM (1) | SMT201900064T1 (enExample) |
| TR (1) | TR201901299T4 (enExample) |
| WO (1) | WO2015081093A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170209408A1 (en) * | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| CN106008657B (zh) * | 2016-05-20 | 2017-11-21 | 天津中医药大学 | 苦蘵苦素i及提取方法及用途 |
| IT201800005336A1 (it) * | 2018-05-14 | 2019-11-14 | Composizioni per uso nel trattamento dell’obesità | |
| US20210106525A1 (en) * | 2019-10-11 | 2021-04-15 | Massachusetts Institute Of Technology | Formulations for gastrointestinal delivery of oligonucleotides |
| CN113599502A (zh) * | 2021-07-22 | 2021-11-05 | 廖儒佳 | 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA791659B (en) | 1978-04-17 | 1980-04-30 | Ici Ltd | Process and apparatus for spraying liquid |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
| HUP9802609A2 (hu) | 1995-06-30 | 1999-03-29 | Eli Lilly And Co. | A diabetes kezelésére szolgáló eljárás |
| ATE259650T1 (de) | 1995-08-17 | 2004-03-15 | Amgen Inc | Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen |
| PT866720E (pt) | 1995-11-22 | 2004-06-30 | Amgen Inc | Proteina ob para aumentar a massa do tecido mole |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| AU2670897A (en) | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
| EP0921820A4 (en) * | 1996-06-20 | 2003-01-15 | Merck & Co Inc | GENETERAPY FOR OBESITY |
| CA2263826A1 (en) | 1996-08-30 | 1998-03-05 | Amgen Inc. | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
| WO1998012224A1 (en) | 1996-09-20 | 1998-03-26 | Hoechst Aktiengesellschaft | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
| PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
| CA2275183A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| ATE223229T1 (de) | 1997-04-17 | 2002-09-15 | Amgen Inc | Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren |
| WO1998055139A1 (en) | 1997-06-06 | 1998-12-10 | Smithkline Beecham Plc | Use of leptin antagonists for the treatment of diabetes |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| JP4199421B2 (ja) | 1998-08-10 | 2008-12-17 | アムジエン・インコーポレーテツド | デキストラン−レプチン結合体、医薬組成物および関連方法 |
| AU6396999A (en) | 1998-10-02 | 2000-04-26 | Amgen, Inc. | Method to determine a predisposition to leptin treatment |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| AU781460B2 (en) | 1999-02-12 | 2005-05-26 | Amgen, Inc. | Glycosylated leptin compositions and related methods |
| AU2002359288B2 (en) | 2001-10-22 | 2008-07-31 | Amgen, Inc. | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| AU2003290563A1 (en) | 2002-10-31 | 2004-05-25 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
| JP4585186B2 (ja) * | 2003-07-31 | 2010-11-24 | 杏林製薬株式会社 | 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤 |
| JP2009541423A (ja) * | 2006-06-23 | 2009-11-26 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ |
| WO2010030395A2 (en) * | 2008-09-15 | 2010-03-18 | Whitehead Institute For Biomedical Research | Withaferin a analogs and uses thereof |
| WO2010053655A2 (en) * | 2008-11-07 | 2010-05-14 | University Of Kansas | Therapeutic methods with withaferin a and analogs |
| WO2012106393A2 (en) * | 2011-02-01 | 2012-08-09 | University Of Kansas | Withanolide isolated from physalis longifolia and analogs and methods of use thereof |
-
2014
- 2014-11-25 PT PT14816018T patent/PT3074033T/pt unknown
- 2014-11-25 US US15/039,743 patent/US20160375039A1/en not_active Abandoned
- 2014-11-25 WO PCT/US2014/067393 patent/WO2015081093A1/en not_active Ceased
- 2014-11-25 JP JP2016554826A patent/JP6672157B2/ja active Active
- 2014-11-25 TR TR2019/01299T patent/TR201901299T4/tr unknown
- 2014-11-25 LT LTEP14816018.7T patent/LT3074033T/lt unknown
- 2014-11-25 SI SI201431046T patent/SI3074033T1/sl unknown
- 2014-11-25 ES ES14816018T patent/ES2709976T3/es active Active
- 2014-11-25 SM SM20190064T patent/SMT201900064T1/it unknown
- 2014-11-25 RS RS20190124A patent/RS58422B1/sr unknown
- 2014-11-25 AU AU2014354831A patent/AU2014354831B2/en not_active Ceased
- 2014-11-25 PL PL14816018T patent/PL3074033T3/pl unknown
- 2014-11-25 CA CA2931826A patent/CA2931826C/en active Active
- 2014-11-25 DK DK14816018.7T patent/DK3074033T3/en active
- 2014-11-25 HR HRP20190219TT patent/HRP20190219T1/hr unknown
- 2014-11-25 EP EP14816018.7A patent/EP3074033B1/en active Active
- 2014-11-25 HU HUE14816018A patent/HUE042196T2/hu unknown
-
2018
- 2018-01-23 AU AU2018200517A patent/AU2018200517B2/en not_active Ceased
-
2019
- 2019-02-05 CY CY20191100155T patent/CY1122551T1/el unknown
- 2019-12-16 JP JP2019226600A patent/JP2020059744A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015081093A1 (en) | 2015-06-04 |
| PT3074033T (pt) | 2019-02-08 |
| HUE042196T2 (hu) | 2019-06-28 |
| TR201901299T4 (tr) | 2019-02-21 |
| SI3074033T1 (sl) | 2019-03-29 |
| LT3074033T (lt) | 2019-02-25 |
| AU2018200517A1 (en) | 2018-02-15 |
| JP6672157B2 (ja) | 2020-03-25 |
| AU2018200517B2 (en) | 2019-12-19 |
| ES2709976T3 (es) | 2019-04-22 |
| PL3074033T3 (pl) | 2019-08-30 |
| DK3074033T3 (en) | 2019-02-11 |
| JP2016537431A (ja) | 2016-12-01 |
| EP3074033B1 (en) | 2018-11-07 |
| EP3074033A1 (en) | 2016-10-05 |
| HRP20190219T1 (hr) | 2019-03-22 |
| SMT201900064T1 (it) | 2019-02-28 |
| CA2931826A1 (en) | 2015-06-04 |
| JP2020059744A (ja) | 2020-04-16 |
| AU2014354831A1 (en) | 2016-06-09 |
| RS58422B1 (sr) | 2019-04-30 |
| AU2014354831B2 (en) | 2017-10-26 |
| CA2931826C (en) | 2021-11-16 |
| US20160375039A1 (en) | 2016-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122551T1 (el) | Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων | |
| CY1125290T1 (el) | Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1123388T1 (el) | Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας | |
| CY1120334T1 (el) | Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων | |
| CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
| CY1121763T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| CY1121549T1 (el) | Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων | |
| CY1120104T1 (el) | Αναστολεις της syk | |
| EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| CY1119487T1 (el) | Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα | |
| CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
| EA201390766A1 (ru) | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ | |
| CY1117559T1 (el) | Ενωση ινδολιου και φαρμακευτικη χρηση αυτου | |
| EA201291300A1 (ru) | Производные нафт-2-илуксусной кислоты для лечения спида | |
| EA201500300A1 (ru) | Способы применения с-мет-модуляторов | |
| CY1119433T1 (el) | Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| DOP2015000308A (es) | Inhibidores de bromodominios | |
| CY1119422T1 (el) | Παραγωγα μπετουλινης | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| EA201391395A1 (ru) | Терапевтические соединения | |
| CY1120378T1 (el) | Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης) | |
| EA201300862A1 (ru) | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления |